Comprehensive Analysis of the Cancer Anorexia-Cachexia Syndrome (CACS) Market 2025-2034: Growth Rates, Trends, and Future Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Projected Compound Annual Growth Rate (CAGR) of the Cancer Anorexia-Cachexia Syndrome (CACS) Market from 2025 to 2034, and What Factors Influence It?
The market for the cancer anorexia-cachexia syndrome (CACS) has seen brisk growth in the past few years. The market is anticipated to expand from $3.51 billion in 2024 to $3.89 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.0%. This surge in the historic period is due to factors such as the escalating number of cancer cases, greater awareness among medical professionals, heightened attention on cancer patients’ life quality, enlargement of clinical trials, and increasing collaborations and partnerships in the pharmaceutical industry.
The market size for cancer anorexia-cachexia syndrome (CACS) is predicted to undergo significant expansion in the upcoming years, arriving at a total value of $5.84 billion by 2029 with a 10.7% compound annual growth rate (CAGR). This upcoming growth trajectory is attributable to factors such as improved cancer survival rates, escalating investments in supportive care for oncology, advancements in personalized medicine, the escalating focus on multimodal treatment methods, and a burgeoning healthcare infrastructure. Key trends set to dominate the forecast period include progress in palliative care, formulation of targeted therapies, technological growth in drug delivery systems, the infusion of AI into drug invention, and the rise of personalized medicine.
Which Drivers Are Expected to Have the Greatest Impact on the Cancer Anorexia-Cachexia Syndrome (CACS) Market’s Growth?
The escalating occurrence of cancer is projected to boost the expansion of the cancer anorexia-cachexia syndrome market in future. Cancer generally refers to various diseases marked by unregulated growth and dispersion of abnormal cells. The global uptick in cancer rates owes to aspects such as an aging populace, lifestyle shifts, environmental hazards, enhancements in detection methods, heightened consciousness, as well as genetic susceptibilities and infections associated with certain cancers. Cancer anorexia-cachexia syndrome (CACS) aims to manage the heavy weight loss and malnutrition characteristically found in cancer patients, with an intention of bettering their overall life quality and treatment outcomes. For example, as revealed by a Macmillan Cancer Support report in August 2024, approximately 3 million people in the UK are grappling with cancer; the figure is estimated to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the escalating occurrence of cancer is amplifying the expansion of the cancer anorexia-cachexia syndrome market. As for the market’s impact due to rising healthcare expenditure, the surge in spending is anticipated to stimulate the cancer anorexia-cachexia syndrome market’s growth in the future. Healthcare expenditure denotes the cumulative financial resources employed on healthcare services, considering both public and private sectors. The rise of healthcare expenditure is prompted by conditions like increasing age population, escalating prevalence of chronic diseases, advancements in medical technologies, and amplified demand for superior healthcare services. Additionally, Cancer Anorexia-Cachexia Syndrome (CACS) is driving up healthcare expenditure by necessitating targeted treatments, nutritional aid, and palliative care for patients, contributing to expensive delivery of cancer-complication management. Per the Office for National Statistics in May 2024, total healthcare spending experienced a 5.6% rise in nominal terms between 2022 and 2023. This was a significant speed-up relative to the 0.9% growth seen in 2022. Thus, the surge in healthcare spending is stimulating the growth of the cancer anorexia-cachexia syndrome market.
Explore Comprehensive Insights Into The Global Cancer Anorexia-Cachexia Syndrome (CACS) Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp
Who Are the Leading Players Fueling Growth in the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.
What Are the Emerging Trends Shaping the Future of the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
Leading companies in the cancer anorexia-cachexia syndrome market are prioritizing the creation of innovative solutions such as monoclonal antibody therapies. These therapies are aimed at boosting treatment efficacy, progressing patient results, and filling clinical gaps. Monoclonal antibody therapies involve the use of lab-created antibodies to focus on specific antigens on cancer cells, augmenting the immune system’s ability to identify and combat these cells. For example, Pfizer Inc., headquartered in the U.S. and renowned in the pharmaceutical and biotechnology sectors, declared encouraging results from a Phase II clinical trial for ponsegromab, a monoclonal antibody targeting Growth/Differentiation Factor 15 (GDF-15), in September 2024. The promising data from this study proposes a potential new treatment pathway for patients afflicted by this disabling condition, where few effective treatments presently exist. The results of the Phase 2 trial indicate substantial advancement in mitigating the inflammatory processes that induce muscle atrophy and weight reduction in cancer patients. This treatment strategy aspires to improve physical functionality and boost overall life quality for cancer patients, symbolizing a landmark evolution in oncology treatment.
Secure Your Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Report Now for Fast and Efficient Delivery!
Which Segments Play a Crucial Role in the Expansion of the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
The cancer anorexia-cachexia syndrome (CACS) market covered in this report is segmented –
1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications
2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions
4) By Route of Administration: Oral, Intravenous, Subcutaneous, Transdermal, Other Route of Administration
5) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors
5) By Other Indications: Combination Therapies, Supportive Care Interventions
Which Regions Are Driving Growth in the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Defining Features of the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
Cancer anorexia-cachexia syndrome (CACS) is a multifactorial condition commonly seen in cancer patients, marked by severe metabolic disturbances. It involves a combination of inflammatory responses, hormonal changes, and altered nutrient utilization, often leading to poor prognosis and treatment resistance.
Browse Through More Similar Reports By The Business Research Company:
Typhoid Vi Polysaccharide Vaccine Global Market Report 2025
Conjugate Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report
Hepatitis B Virus (HBV) Global Market Report 2025
https://thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
